Common Stock, $0.0001 par value per share
- Symbol
- IXHL
- Exchange
- NASDAQ
- Classification
- COMMON
- Status
- Current
Current Report · Items 7.01, 9.01 · 8-K
Incannex Healthcare Inc.
IXHLNASDAQEQUITYCurrent
Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure. On July 23, 2026, Incannex Healthcare Inc. (the “Company”) issued the press release furnished as Exhibit 99.1. The information contained in Item 7.01 in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Ex…
Press release in this filing
Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea →Company context
Incannex Healthcare Inc. is a clinical-stage biopharmaceutical company developing innovative combination therapies and next-generation medicines for conditions with significant unmet medical need. The Company’s lead programs include IHL-42X for obstructive sleep apnea and PSX-001 for generalized anxiety disorder. Incannex is committed to advancing therapies that address multiple biological pathways with the goal of improving patient outcomes and creating long-term shareholder value. For more information, please visit www.incannex.com.
Current securities
Historical securities (1)
Registered securities in this filing
Incannex Healthcare Inc. · 8-K · Filed 2026-07-23
Disclosure sections
Item 7.01Item 7.01 - Regulation FD Disclosure
Item
7.01 Regulation FD Disclosure.
On July
23, 2026, Incannex Healthcare Inc. (the “Company”) issued the press release furnished as Exhibit 99.1.
The information
contained in Item 7.01 in this Current Report on Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be
deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”),
or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities
Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.
Filed exhibits (1)
EX-99.1 2 ea029867401ex99-1.htm PRESS RELEASE DATED AS OF JULY 23, 2026 Exhibit 99.1 Incannex Commences Participant Screening in DReAMzz Phase 2 Study of IHL-42X for Obstructive Sleep Apnea First clinical sites approved and actively screening potential participants Represents another major milestone in the advancement of IHL-42X towards Phase III development IHL-42X has received FDA Fast Track designation, highlighting its potential to address the significant unmet medical need in obstructive sleep apnea and supporting a potentially expedited regulatory pathway Study designed to optimize both objective sleep metrics and patient-reported outcomes to support regulatory approval and commercial differentiation Builds upon previously announced positive Phase 2 data demonstrating up to 83% reduction in AHI and significant improvements across multiple patient-reported outcome measures Obstructive sleep apnea affects an estimated one billion people globally, with no FDA-approved oral pharmaceutical therapies currently available MELBOURNE, Australia and NEW YORK, 23 July, 2026 - Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company…
Open exhibit ↗